Evidence map›Paper›PMID 21603121›Full record

ArticleJournal of clinical bioinformatics2011

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.

Mosmi Surati, Matthew Robinson, Suvobroto Nandi, Leonardo Faoro, Carley Demchuk, Cleo E Rolle, Rajani Kanteti, Benjamin D Ferguson, Rifat Hasina, Tara C Gangadhar and 14 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of clinical bioinformatics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 2 institutions in 1 country.

Mosmi SuratiPritzker School of Medicine, University of Chicago Pritzker School of Medicine, 924 E. 57 St., Chicago, IL 60637.
Matthew Robinson
Suvobroto Nandi
Leonardo Faoro
Carley Demchuk
Cleo E Rolle
Rajani Kanteti
Benjamin D Ferguson
Rifat Hasina
Tara C Gangadhar
April K Salama
Qudsia Arif
Colin Kirchner
Eneida Mendonca
Nicholas Campbell
Suwicha Limvorasak
Victoria Villaflor
Thomas A Hensing
Thomas Krausz
Everett E Vokes
Aliya N Husain
Mark K Ferguson
Theodore G Karrison
Ravi Salgia
University of Chicago · USNorthShore University HealthSystem · US

Funding

Role of c-Met in SCLC and Potential for Novel TherapyR01CA100750 · NCI · UNIVERSITY OF CHICAGO · PI SALGIA, RAVI · 2004 to 2012
$2.2M
Role of Paxillin in Lung CancerR01CA129501 · NCI · UNIVERSITY OF CHICAGO · PI SALGIA, RAVI · 2008 to 2012
$1.8M
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)R01CA125541 · NCI · UNIVERSITY OF CHICAGO · PI SALGIA, RAVI · 2007 to 2011
$1.4M
NCI NIH HHS R01 CA100750NCI NIH HHS R01 CA125541NCI NIH HHS R01 CA129501
6 · The paper itself

Abstract

backgroundIn recent years, there has been tremendous growth and interest in translational research, particularly in cancer biology. This area of study clearly establishes the connection between laboratory experimentation and practical human application. Though it is common for laboratory and clinical data regarding patient specimens to be maintained separately, the storage of such heterogeneous data in one database offers many benefits as it may facilitate more rapid accession of data and provide researchers access to greater numbers of tissue samples. DESCRIPTION: The Thoracic Oncology Program Database Project was developed to serve as a repository for well-annotated cancer specimen, clinical, genomic, and proteomic data obtained from tumor tissue studies. The TOPDP is not merely a library-it is a dynamic tool that may be used for data mining and exploratory analysis. Using the example of non-small cell lung cancer cases within the database, this study will demonstrate how clinical data may be combined with proteomic analyses of patient tissue samples in determining the functional relevance of protein over and under expression in this disease. Clinical data for 1323 patients with non-small cell lung cancer has been captured to date. Proteomic studies have been performed on tissue samples from 105 of these patients. These tissues have been analyzed for the expression of 33 different protein biomarkers using tissue microarrays. The expression of 15 potential biomarkers was found to be significantly higher in tumor versus matched normal tissue. Proteins belonging to the receptor tyrosine kinase family were particularly likely to be over expressed in tumor tissues. There was no difference in protein expression across various histologies or stages of non-small cell lung cancer. Though not differentially expressed between tumor and non-tumor tissues, the over expression of the glucocorticoid receptor (GR) was associated improved overall survival. However, this finding is preliminary and warrants further investigation.

conclusionThough the database project is still under development, the application of such a database has the potential to enhance our understanding of cancer biology and will help researchers to identify targets to modify the course of thoracic malignancies.

Identifiers

PMID21603121
PMCPMC3164615
OpenAlexW2133103143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.